Monte Rosa Tx - GLUE Quarterly EPS earnings growth

Corporate company logo of Monte Rosa Therapeutics, Inc. (GLUE)

The development of "molecular glues" to eliminate undruggable proteins drives the dynamics of the quarterly net income per share growth rate, which currently stands at 109.00. Transparent management and M&A expertise strengthen the position of Monte Rosa Therapeutics (GLUE). High clinical costs and patent protection create an insurmountable barrier to entry for new players in the targeted therapy segment.

monterosatx.com (GLUE) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/10/2026

Analytical breakdowns for Monte Rosa Therapeutics

- share price and consensus valuation forecast:
Stock Quotes Monte Rosa Therapeutics, Inc.|GLUE - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Monte Rosa Tx|GLUE - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Monte Rosa Therapeutics|GLUE - Accounting Value of Company|Market Capitalization to Book Value Ratio monterosatx.com|GLUE - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital Monte Rosa Therapeutics|GLUE - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Monte Rosa Therapeutics|GLUE - Company Cumulative Indebtedness|Debts to Book Capitalization Monte Rosa Tx|GLUE - Long-Term Debt|Company Short-Term Debts Monte Rosa Therapeutics|Quick Liquidity Indicator monterosatx.com
- earnings and market multiples details:
GLUE - Final Profit|Future Profit Monte Rosa Therapeutics|GLUE - Market Price to Net Income Ratio|Forward P/E Multiple Monte Rosa Tx|GLUE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Monte Rosa Tx|GLUE - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Monte Rosa Therapeutics|GLUE - Earnings per share for the trailing year|Quarterly EPS earnings growth monterosatx.com|GLUE - Earnings growth in current year|Net earnings per share growth forecast for next year Monte Rosa Therapeutics
Fundamental company valuation:Monte Rosa Therapeutics, Inc. - GLUE
Flagship merchandise of monterosatx.com

For the long-term investor, the reliability of Monte Rosa Therapeutics (GLUE) is determined by its ability to monetize unique developments. Quarterly EPS growth measures the dynamics of net profit per share, reflecting the actual efficiency of capital management. By analyzing this chart of quarterly earnings per share, one can assess the impact of strict FDA regulations on financial results. Patent protection of the IT platform creates the foundation for the future growth of this metric. The stability of this metric confirms the business's resilience under high regulatory pressure.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Kymera Corp|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences (IDYA)|ELVN (enliventherapeutics.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals, Inc.)|Net earnings per share growth for the trailing year Relay Therapeutics Inc|Nurix Pharma - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Corp|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (Immuneering) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Therapeutics Inc CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Bio Green Med Solution Inc. - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months GlycoMimetics Corp GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks Therapeutics, Inc. (SWTX)